Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery

Conditions

• Coronary Artery Bypass Graft

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• MIB-626 — DRUG
  An orally-administered stable crystalline tablet formulation of NMN
• Placebo — OTHER
  matching placebo tablets

Study Details

The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.

Key Dates

First listed

Jun 10, 2025

Start date

Jun 10, 2026

Status verified

Jun 2026

Primary completion

Oct 1, 2028

Completion

Jan 1, 2029

Study Design

Enrollment

90 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: NMN (MIB-626) for 7 days preoperatively, on day of surgery, and for 4 days postoperatively
  NMN (MIB-626) 1000 mg PO daily, for 7 days preoperatively, on day of surgery, and for 4 days postoperatively
• Experimental: NMN administered for 2 days preoperatively, on the day of surgery, and for 4 days postoperatively
  NMN (MIB-626) 1,000 mg PO twice daily, administered for 2 days preoperatively, on the day of surgery, and for 4 days postoperatively
• Placebo Comparator: Placebo
  Placebo administered for 7 days preoperatively, on the day of surgery, and for 4 days postoperatively

Primary Outcome Measure

NAD+ concentration in the myocardial tissue [ Time Frame: Intraoperatively (single time point) ]

Central Contacts

• Shalender Bhasin, MB,BS
  617-525-9150
  [email protected]
• David E Leaf, MD
  617-732-5951
  [email protected]

Locations (1)

Find similar trials in Boston, MA